Supplemental material
OncoImmunology
Volume 12, 2023 - Issue 1
Original Research
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response
Laura Rubio-Péreza Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain;b Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;c H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain;d Chair for Immunology UFV/Merck, Universidad Francisco de Vitoria (UFV), Madrid, Spain
https://orcid.org/0000-0002-2877-6092View further author information
https://orcid.org/0000-0002-2877-6092View further author information, Rodrigo Lázaro-Gorinesa Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain;b Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;c H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spainhttps://orcid.org/0000-0002-6885-3486View further author information
https://orcid.org/0000-0002-6885-3486View further author information, Seandean L. Harwoode Department of Molecular Biology and Genetics, Aarhus University, Aarhus C, Denmarkhttps://orcid.org/0000-0003-4654-8832View further author information
https://orcid.org/0000-0003-4654-8832View further author information, Marta Comptef Department of Antibody Engineering, Leadartis SL, QUBE Technology Park, Madrid, Spainhttps://orcid.org/0000-0002-7138-9266View further author information
https://orcid.org/0000-0002-7138-9266View further author information, Rocío Navarrof Department of Antibody Engineering, Leadartis SL, QUBE Technology Park, Madrid, Spainhttps://orcid.org/0000-0002-0083-7711View further author information
https://orcid.org/0000-0002-0083-7711View further author information, Antonio Tapia-Galisteoa Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain;b Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;c H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spainhttps://orcid.org/0000-0002-0507-8435View further author information
https://orcid.org/0000-0002-0507-8435View further author information, Jaume Bonetg Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerlandhttps://orcid.org/0000-0001-5210-4387View further author information
https://orcid.org/0000-0001-5210-4387View further author information, Belén Blancoa Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain;b Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;c H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spainhttps://orcid.org/0000-0001-5085-7756View further author information
https://orcid.org/0000-0001-5085-7756View further author information, Simon Lykkemarkh Immunotherapy and Cell Engineering Laboratory, Department of Engineering, Aarhus University, Aarhus C, Denmarkhttps://orcid.org/0000-0001-8920-6926View further author information
https://orcid.org/0000-0001-8920-6926View further author information, Ángel Ramírez-Fernándeza Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain;b Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;c H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spainhttps://orcid.org/0000-0002-3265-6878View further author information
https://orcid.org/0000-0002-3265-6878View further author information, Mariola Ferreras-Gutiérrezi Centro de Investigaciones Biológicas Margarita Salas (CIB), CSIC, Madrid, Spainhttps://orcid.org/0000-0003-4421-3158View further author information
https://orcid.org/0000-0003-4421-3158View further author information, Carmen Domínguez-Alonsoa Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain;b Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;c H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spainhttps://orcid.org/0000-0002-0446-9629View further author information
https://orcid.org/0000-0002-0446-9629View further author information, Laura Díez-Alonsoa Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain;b Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;c H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spainhttps://orcid.org/0000-0002-9545-6910View further author information
https://orcid.org/0000-0002-9545-6910View further author information, Alejandro Segura-Tudelaa Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain;b Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;c H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spainhttps://orcid.org/0000-0002-5506-0153View further author information
https://orcid.org/0000-0002-5506-0153View further author information, , , Francisco J. Blancoi Centro de Investigaciones Biológicas Margarita Salas (CIB), CSIC, Madrid, Spainhttps://orcid.org/0000-0003-2545-4319View further author information
https://orcid.org/0000-0003-2545-4319View further author information, Cruz Santosj Faculty of Experimental Sciences, Universidad Francisco de Vitoria (UFV), Madrid, Spainhttps://orcid.org/0000-0001-5164-5050View further author information
https://orcid.org/0000-0001-5164-5050View further author information, José L. Rodríguez-Peraltok Department of Pathology, Hospital Universitario 12 de Octubre, Madrid, Spain;l Department of Pathology, Universidad Complutense, Madrid, Spain;m Cutaneous Oncology Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;n Centro de Investigación Biomédica en Red en Oncología (CIBERONC), Madrid, Spainhttps://orcid.org/0000-0002-6578-7153View further author information
https://orcid.org/0000-0002-6578-7153View further author information, Laura Sanzn Centro de Investigación Biomédica en Red en Oncología (CIBERONC), Madrid, Spain;o Molecular Immunology Unit, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spainhttps://orcid.org/0000-0002-3119-3218View further author information
https://orcid.org/0000-0002-3119-3218View further author information & Luis Álvarez-Vallinaa Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain;b Immuno-Oncology and Immunotherapy Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, Spain;c H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain;d Chair for Immunology UFV/Merck, Universidad Francisco de Vitoria (UFV), Madrid, SpainCorrespondence[email protected]
https://orcid.org/0000-0003-3053-6757View further author information
https://orcid.org/0000-0003-3053-6757View further author information show all